In the last announcement:
A second interim analysis by the trial’s independent Data Safety Monitoring Board is expected in early November, with completion of patient enrollment expected in December
That would imply that 45% have been dosed by (at least) early-Oct, plus 30 day mortality rate known.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.71 |
Change
0.035(2.10%) |
Mkt cap ! $2.188B | |||
| Open | High | Low | Value | Volume |
| $1.67 | $1.74 | $1.67 | $4.300M | 2.511M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 22 | 27804 | $1.71 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.71 | 24577 | 24 |
View Market Depth
| Last trade - 14.37pm 15/07/2025 (20 minute delay) ? |
| MSB (ASX) Chart |